Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays

Leukemia

Volumn 13, Issue 8, 1999, Pages 1200-1206

  Ghaffari, S ^a   Daley, G Q ^a,b   Lodish, H F ^a,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

BCR ABL; Chronic myeloid leukemia (CML); Growth factor independence; Signal transduction

Indexed keywords

BCR ABL PROTEIN; CYTOKINE; GROWTH FACTOR;

ANIMAL MODEL; ASSAY; CANCER MODEL; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIESIS; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032841181     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401467     Document Type: Review

References (66)

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550-554.
3. Walker LC, Ganesan TS, Dhut S, Gibbons B, Lister TA, Rothbard J, Young BD. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia. Nature 1987; 329: 851-853.
4. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature 1987; 325: 631-635.
5. Kurzrock R, Shtalrid M, Talpaz M, Kloetzer WS, Gutterman JU. Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood 1987; 70: 1584-1588.
6. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88: 2410-2414.
7. Emilia G, Luppi M, Marasca R, Torelli G. Relationship between BCR/ABL fusion proteins and leukemia phenotype (letter; comment). Blood 1997; 89: 3889.
8. Mittre H, Leymarie P, Macro M, Leporrier M. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease? (letter; comment). Blood 1997; 89: 4239-4241.
9. Briz M, Vilches C, Cabrera R, Fores R, Fernandez MN. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript (letter). Blood 1997; 90: 5024-5025.
10. Eaves CJ, Eaves AC. Cell culture studies in CML. Baillières Clin Haematol 1987; 1: 931-961.
11. Daley CQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
12. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990; 344: 251-253.
13. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, Baltimore D. Efficient and rapid induction of a chronic myeloid leukemia-like myeloproliferative disease in mice receiving P210 bcr-abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
14. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myeloid leukemia. Blood 1998; 92: 3829-3840.
15. Eaves AC, Eaves CJ. Abnormalities in the erythroid progenitor compartments in patients with chronic myelogenous leukemia (CML). Exp Hematol 1979; 5: 65-75.
16. Issaad C, Vainchenker W. Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Blood 1994; 84: 3447-3456.
17. Ghaffari S, Gerlach M, Wu H, Lodish H, Daley G. The leukemia oncoprotein BCR-ABL complements for the erythropoietin receptor. Exp Hematol 1998; 26: 815a.
18. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillières Clin Haematol 1997; 10: 223-231.
19. Sattler M, Salgia R. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 1997; 8: 63-79.
20. Wang JY, Ledley F, Goff S, Lee R, Groner Y, Baltimore D. The mouse c-abl locus: molecular cloning and characterization. Cell 1984; 36: 349-356.
21. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986; 47: 277-284.
22. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
23. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993; 12: 1533-1546.
24. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13: 7587-7595.
25. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991; 66: 161-171.
26. Muller AJ, Pendergast AM, Havlik MH, Puil L, Pawson T, Witte ON. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol Cell Biol 1992; 12: 5087-5093.
27. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell 1991; 67: 459-468.
28. Diekmann D, Brill S, Garrett MD, Totty N, Hsuan J, Monfries C, Hall C, Lim L, Hall A. Bcr encodes a GTPase-activating protein for p21 rac. Nature 1991; 351: 400-402.
29. Whitehead IP, Campbell S, Rossman KL, Der CJ. Dbl family proteins. Biochim Biophys Acta 1997; 1332: F1-F23.
30. Chuang TH, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch GM. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci USA 1995; 92: 10282-10286.
31. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 1989; 9: 1866-1874.
32. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995; 82: 981-988.
33. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 1988; 85: 9312-9316.
34. Ghaffari S, Wu H, Neumann D, Klucher K, Lodish H, Daley G. BCR-ABL complementation of EPO-R signaling pathways. Blood 1997; 90: 393a.
35. Gishizky ML, Witte ON. Initiation of deregulated growth of multi-potent progenitor cells by bcr-abl in vitro. Science 1992; 256: 836-839.
36. + cells from patients with CML. Exp Hematol 1998; 26: 800a.
37. Hariharan IK, Adams JM, Cory S. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 1988; 3: 387-399.
38. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997; 90: 64-69.
39. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, Witte ON. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 1991; 11: 1785-1792.
40. McWhirter JR, Wang JY. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 1991; 11: 1553-1565.
41. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185.
42. Muller AJ, Pendergast AM, Parmar K, Havlik MH, Rosenberg N, Witte ON. En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase. Proc Natl Acad Sci USA 1993; 90: 3457-3461.
43. Maru Y, Witte ON, Shibuya M. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Lett 1996; 379: 244-246.
44. Skorski T, Nieborowska-Skorska M, Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak M, Martinez R, Majewski M, Wong A, Perussia B, Calabretta B. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. Blood 1998; 91: 406-418.
45. Pendergast AM, Gishizky ML, Havlik MH, Witte ON. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol 1993; 13: 1728-1736.
46. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 1995; 15: 5531-5541.
47. Ilaria R Jr, Van Etten RA. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 1995; 86: 3897-3904.
48. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure, activation, and intracellular signal transduction. Trends Endocrinol 1999; 10: 18-23.
49. Damen JE, Mui AL, Puil L, Pawson T, Krystal G. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood 1993; 81: 3204-3210.
50. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 1995; 14: 5557-5568.
51. Klingmuller U, Bergelson S, Hsiao JG, Lodish HF. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci USA 1996; 93: 8324-8328.
52. Klingmuller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci USA 1997; 94: 3016-3021.
53. Wu H, Klingmuller U, Acurio A, Hsiao JG, Lodish HF. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc Natl Acad Sci USA 1997; 94: 1806-1810.
54. Shaoguang L, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR-ABL oncogene induce similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412.
55. Socolovsky M, Lodish HF Daley GQ. Control of hematopoietic differentiation: lack of specificity in signaling by cytokine receptors. Proc Natl Acad Sci USA 1998; 95: 6573-6575.
56. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887-5895.
57. Kinoshita T, Yokota T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J 1995; 14: 266-275.
58. Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 1998; 16: 489-496.
59. Longmore GD, Pharr P, Lodish HF. Mutation in murine erythropoietin receptor induces erythropoietin-independent erythroid proliferation in vitro, polycythemia in vivo. Leukemia 1992; 6: 130S-134S.
60. Renshaw MW, McWhirter JR, Wang JY. The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 1995; 15: 1286-1293.
61. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996; 87: 3883-3891.
62. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM. Activation of betal integrins on CML progenitors reveals cooperation between betal integrins and CD44 in the regulation of adhesion and proliferation. Leukemia 1997; 11: 822-829.
63. Ghaffari S, Dougherty GJ, Eaves AC, Eaves CJ. Diverse effects of anti-CD44 antibodies on the stromal cell-mediated support of normal but not leukaemic (CML) haemopoiesis in vitro. Br J Haematol 1997; 97: 22-28.
64. Voncken JW, van Schaick H, Kaartinen V, Deemer K, Coates T, Landing B, Pattengale P, Dorseuil O, Bokoch GM, Groffen J et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell 1995; 80: 719-728.
65. Roberts AW, Kim C, Zhen L, Lowe JB, Kapur R, Petryniak B, Spaetti A, Pollock JD, Borneo JB, Bradford GB, Atkinson SJ, Dinauer MC. Deficiency of the hematopoietic cell-specific Rho family GTP-ase Rac2 is characterized by abnormalities in neutrophil function and host defense. Cell 1999; 10: 183-196.
66. Muller AJ, Young JC, Pendergast AM, Pondel M, Littman DR, Witte ON. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 1991; 11: 1785-1792.